This site is intended for healthcare professionals

Phase III MAESTRO-NAFLD-1 study of MGL 3196 shows it to be safe and well-tolerated in non-alcoholic fatty liver disease.

Read time: 1 mins
Published:1st Feb 2022
Madrigal Pharmaceuticals announced positive topline clinical data from the placebo-controlled, double-blind portion of its Phase III MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) safety study of MGL 3196 (resmetirom).

The 52-week study demonstrated that resmetirom was safe and well-tolerated at 80 and 100 mg once a day dosing. Additionally, resmetirom helped patients with presumed non-alcoholic steatohepatitis (NASH) achieve significant, clinically relevant reductions in liver fat and atherogenic lipids.

Hierarchically-controlled key secondary endpoints were achieved for both the 80 and 100 mg resmetirom dose groups. Resmetirom provided significant reductions in liver fat as measured by MRI-PDFF and reduced atherogenic lipids, including LDLc, apolipoprotein B and triglycerides. Although both arms were randomized in MAESTRO-NAFLD-1, lipid reductions were numerically greater in the 100 mg open label treatment arm compared to the 100 mg double-blind arm. Patients in the open-label active 100 mg treatment arm were less impacted by COVID-related dose interruptions than double-blind patients.

Resmetirom was safe and well-tolerated at the 80 mg dose and also importantly at the top dose of 100 mg in MAESTRO-NAFLD-1. Adverse events observed in the MAESTRO-NAFLD-1 trial were generally mild to moderate in severity. The frequency of serious adverse events was similar across treatment arms and discontinuation for adverse events was low.

Condition: Non Alcoholic Fatty Liver Disease (NAFLD)
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.